Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of V116 in adults aged 50 years or older previously vaccinated against pneumococcal infection
MOH_2022-06-22_011865Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease (5 cohorts), sponsored by Merck & Co. Primary endpoints: Safety, Tolerability and 1 more. Started Jun 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on MOH_2022-06-22_011865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-22_011865.